FindTrial
Sign In

Impact of artificial intelligence based scoring of hormone expression in breast cancer on treatment decision making.

Validation of artificial intelligence (AI) based pathology solution in scoring of biomarker expression in breast cancer and its impact on clinical decision making in breast cancer therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/03/031926
Enrollment
75
Registered
2021-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Applied Materials India PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female patients, post-surgery with diagnosed breast carcinoma subjected to immunohistochemical analysis of hormone receptors(ER, PR, Her2-neu and Ki67) on the breast specimen.

Exclusion criteria

Exclusion criteria: Cases were consent could not be obtained

Design outcomes

Primary

MeasureTime frame
Utility and effectiveness of computer assisted artificial intelligence (AI) based analysis to objectively quantify the biomarker expression in breast cancer.Timepoint: 4 months—

Secondary

MeasureTime frame
Impact of AI based scoring in deciding therapy modulation in patient diagnosed with breast cancer.Timepoint: 4 months—

Countries

India

Contacts

Public ContactDr Brij Mohan Kumar Singh

Kasturba Medical College, Manipal

brij.singh@manipal.edu9663984859

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026